Thermo Fisher Scientific Renews Agreement with Roche for Procalcitonin Technology

Thermo Fisher Scientific has reached a new agreement with Roche for the use of its Procalcitonin technology.

It is currently available as an automated immunoassay on the Roche Elecsys cobas e platforms in all countries outside of the US.

The deal will continue a long running relationship between the two organisations.

Marc Tremblay, president of Thermo Fisher Scientific's clinical diagnostics business, said: "The continuation of our close collaboration with Roche significantly strengthens our ability to make our biomarker test globally available to a broader patient population.

"Early diagnosis is the key for preventing sepsis a medical condition that is still very common today and accounts for hundreds of thousands of deaths each year."

Between 20 and 30 million patients around the world are affected by sepsis every year and it claims more lives than bowel and breast cancer combined.

Despite advances in modern medicine, sepsis is the primary cause of death from infection with hospital mortality rates between 30 and 60%.